ストックスクリーナーアプリを入手
3.73
1.58%
-0.06
アフターアワーズ：
3.91
0.18
+4.83%
前日終値:
$3.79
開ける：
$3.75
24時間の取引高:
472.23K
Relative Volume:
1.32
時価総額：
$261.07M
収益：
$63.39M
当期純損益:
$-219.51M
株価収益率:
-1.1792
EPS:
-3.1631
ネットキャッシュフロー:
$-231.83M
1週間 パフォーマンス:
+1.36%
1か月 パフォーマンス:
-13.26%
6か月 パフォーマンス:
-23.88%
1年 パフォーマンス:
-53.37%
1日の値動き範囲:
$3.68
$3.805
1週間の範囲:
$3.3301
$4.0386
52週間の値動き範囲:
$3.3301
$9.1592
Bicycle Therapeutics Plc Adr Stock (BCYC) Company Profile
名前
Bicycle Therapeutics Plc Adr
セクター
電話
011441223261503
住所
BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE
Compare BCYC vs VRTX, MRNA, REGN, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BCYC
Bicycle Therapeutics Plc Adr
|
3.73 | 257.92M | 63.39M | -219.51M | -231.83M | -3.1631 |
VRTX
Vertex Pharmaceuticals Inc
|
505.64 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
196.48 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
742.12 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
928.44 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
200.87 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bicycle Therapeutics Plc Adr Stock (BCYC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-24 | 開始されました | Truist | Hold |
| 2025-10-31 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-08 | 開始されました | Stephens | Equal-Weight |
| 2024-09-06 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-08-07 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2023-09-11 | アップグレード | B. Riley Securities | Neutral → Buy |
| 2022-08-31 | 開始されました | Cowen | Outperform |
| 2022-07-28 | 開始されました | Barclays | Overweight |
| 2022-07-06 | 再開されました | Canaccord Genuity | Buy |
| 2022-04-13 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2022-04-07 | 再開されました | Cantor Fitzgerald | Overweight |
| 2022-02-14 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-12-17 | 開始されました | SVB Leerink | Outperform |
| 2021-12-09 | 開始されました | Needham | Buy |
| 2021-09-30 | 開始されました | B. Riley Securities | Buy |
| 2021-04-20 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-10-12 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-06-12 | 開始されました | Oppenheimer | Outperform |
| 2020-04-17 | 開始されました | H.C. Wainwright | Buy |
| 2019-11-14 | 開始されました | ROTH Capital | Buy |
| 2019-09-11 | アップグレード | Goldman | Neutral → Buy |
| 2019-06-17 | 開始されました | Canaccord Genuity | Buy |
| 2019-06-17 | 開始されました | Goldman | Neutral |
| 2019-06-17 | 開始されました | Jefferies | Buy |
| 2019-06-17 | 開始されました | Piper Jaffray | Overweight |
すべてを表示
Bicycle Therapeutics Plc Adr (BCYC) 最新ニュース
Non-operating income (total) of Bicycle Therapeutics Plc Sponsored ADR – HAN:50BA - TradingView
Bicycle Therapeutics plcADR Peer Comparison – Compare with Others - Value Research
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Renaissance Technologies LLC Buys 412,700 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat
Bicycle Therapeutics plc (BCYC) Investigation: Bronstein, Gewirtz - The National Law Review
Bicycle Therapeutics (BCYC) Earnings Date and Reports 2026 - MarketBeat
Siren L.L.C. Trims Position in Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat
ETFs Investing in Bicycle Therapeutics Plc Sponsored ADR Stocks - TradingView
Tarsus Pharmaceuticals (TARS) moves 7.5% higher: Will this strength last? - MSN
Tarsus Pharmaceuticals (TARS) Moves 7.5% Higher: Will This Strength Last? - Yahoo Finance
Price to earnings forward of Bicycle Therapeutics Plc Sponsored ADR – FWB:50BA - TradingView
Enterprise value to EBIT forward of Bicycle Therapeutics Plc Sponsored ADR – FWB:50BA - TradingView
Bicycle Therapeutics Plc Sponsored ADR Actuals & Estimates (NASDAQ:BCYC) - TradingView
Price to sales forward of Bicycle Therapeutics Plc Sponsored ADR – FWB:50BA - TradingView
50BA Forecast — Price Target — Prediction for 2027 - TradingView
Bicycle Therapeutics shareholders approve all proposals at annual general meeting - Investing.com South Africa
BCYC - Finviz
Bicycle Therapeutics’ SWOT analysis: stock navigates trial delays - Investing.com
After plunging 20.2% in 4 weeks, here's why the trend might reverse for Bicycle Therapeutics (BCYC) - MSN
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Sees Significant Increase in Short Interest - MarketBeat
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results - ChartMill
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Bicycle Therapeutics (BCYC) loses 19.0% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Bicycle Therapeutics (BCYC) schedules 2026 AGM with director, pay and auditor votes - Stock Titan
Peptide Drug Conjugate Market Landscape Report 2026: A $1.5 Billion Opportunity by 2031 - GlobeNewswire Inc.
Bicycle Therapeutics doses first patient in pancreatic cancer trial By Investing.com - Investing.com South Africa
Bicycle Therapeutics doses first patient in pancreatic cancer trial - Investing.com
Wall Street Analysts Believe Bicycle Therapeutics (BCYC) Could Rally 137.88%: Here's is How to Trade - Yahoo Finance
Bicycle Therapeutics (NASDAQ:BCYC) CEO Kevin Lee Sells 5,967 Shares of Stock - MarketBeat
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Bicycle Therapeutics (BCYC) - Yahoo Finance
Bicycle Therapeutics (BCYC) Loses 19.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Bicycle Therapeutics (BCYC) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Morgan Stanley reiterates Bicycle Therapeutics stock rating on program shift - Investing.com
Bicycle Therapeutics announces leadership changes for next phase - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bicycle Therapeutics plcBCYC - PR Newswire
Investigation Alert: Bicycle Therapeutics plc (BCYC) Under ScrutinyContact Levi & Korsinsky for Details - ACCESS Newswire
BCYC: Q3 2025 featured higher R&D costs, a $59.1M net loss, and strong cash reserves supporting clinical progress - TradingView
Bicycle Therapeutics (BCYC) Stock Price, News & Analysis - MarketBeat
Bicycle Therapeutics’ SWOT analysis: stock faces pivotal phase amid clinical progress - Investing.com
BCYC: Cost realignment and pipeline progress extend financial runway into 2028 amid higher R&D spend - TradingView
BCYC: Q1 2025 net loss widened to $60.8M on higher R&D, with $793M cash to fund near-term operations - TradingView
Bicycle therapeutics CFO Alethia Young sells $1,724 in stock By Investing.com - Investing.com India
Bicycle Therapeutics chief accounting officer sells shares worth $2,499 - Investing.com
Bicycle Therapeutics reshuffles leadership, aims for oncology advances - Investing.com
Bicycle Therapeutics CEO Lee sells shares worth $172,952 - Investing.com
Bicycle therapeutics executive sells shares worth over $21k - Investing.com
Europe Peptide Drug Conjugates Market Size & Outlook, 2030 - Grand View Research
Bicycle Therapeutics Plc Adr (BCYC) 財務データ
収益
当期純利益
現金流量
EPS
Bicycle Therapeutics Plc Adr (BCYC) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Skynner Michael | CHIEF SCIENTIFIC OFFICER |
Oct 02 '26 |
Sale |
3.47 |
1,942 |
6,739 |
155,229 |
| Skynner Michael | CHIEF SCIENTIFIC OFFICER |
Oct 05 '26 |
Sale |
3.57 |
503 |
1,796 |
154,726 |
| Hannay Michael Charles Ferguso | CHIEF PROD & SUPPLY CHAIN OFF |
Oct 02 '26 |
Sale |
3.47 |
1,572 |
5,455 |
92,803 |
| Hannay Michael Charles Ferguso | CHIEF PROD & SUPPLY CHAIN OFF |
Oct 05 '26 |
Sale |
3.57 |
242 |
864 |
92,561 |
| Perry Jennifer Scott | Chief Operating Officer |
Oct 02 '26 |
Sale |
3.47 |
1,094 |
3,796 |
89,958 |
| Perry Jennifer Scott | Chief Operating Officer |
Oct 05 '26 |
Sale |
3.74 |
406 |
1,517 |
89,552 |
| Lee Kevin | CHIEF EXECUTIVE OFFICER |
Oct 02 '26 |
Sale |
3.47 |
6,167 |
21,399 |
597,504 |
| Lee Kevin | CHIEF EXECUTIVE OFFICER |
Oct 05 '26 |
Sale |
3.57 |
1,638 |
5,848 |
595,866 |
| Thompson Travis Alvin | Chief Financial Officer |
Oct 02 '26 |
Sale |
3.47 |
893 |
3,099 |
64,528 |
| Thompson Travis Alvin | Chief Financial Officer |
Oct 05 '26 |
Sale |
3.57 |
79 |
282 |
64,449 |
0.50%
0.57%
大文字化:
|
ボリューム (24 時間):